pharma · Pancreatic Adenocarcinoma · Cancer · ACTU
Actuate Therapeutics
ACTUATE THERAPEUTICS, INC.
Actuate Therapeutics clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1751 River Run, Suite 400, Fort Worth, Texas 76107, US
- Founded
- 2015
- Employees
- 16
- Programs
- 12
- Drugs
- 11
- Patents
- 7
Actuate Therapeutics projects
9 ClinicalTrials.gov programs sponsored by Actuate Therapeutics.
Actuate Therapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
1801
ACTUATE THERAPEUTICS, INC.
Refractory Hematologic Malignancies or Solid Tumors
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Cancer
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Pancreatic Adenocarcinoma
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Salivary Gland Cancer
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Salivary Gland Carcinoma
1 trial -
FOLFIRNINOX
ACTUATE THERAPEUTICS, INC.
Pancreatic Adenocarcinoma
1 trial -
Gemcitabine
ACTUATE THERAPEUTICS, INC.
Sarcoma
1 trial -
Gemcitabine
ACTUATE THERAPEUTICS, INC.
Soft Tissue Sarcoma
1 trial -
Ruxolitinib
ACTUATE THERAPEUTICS, INC.
Myelofibrosis
1 trial
Frequently asked questions
How many clinical projects does Actuate Therapeutics have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.